BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rituxan (Rituximab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rituxan (Rituximab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03352765-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT03352765)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: A Phase I Study of Benda
 mustine and Melphalan Conditioning and Autologous Stem Cell Transplantatio
 n for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphom
 a in Elderly Patients\nEstimated primary completion: November 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03352765
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00692939-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT00692939)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Autologous Stem Cell T
 ransplantation for Crohn's Disease\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT00692939
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03467867-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03467867)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed
 /Refractory CLL\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03467867
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) 
 With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Lar
 ge B-cell Lymphoma\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04442022
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01479842-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT01479842)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Follicular Lymphoma.\nStudy: Ri
 tuxan/Bendamustine/PCI-32765 in Relapsed DLBCL\, MCL\, or Indolent Non-Hod
 gkin's Lymphoma\nEstimated primary completion: 1 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT01479842
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05065554-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05065554)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: ACALA-R In Predominantly
  Demyelinating IgM Mediated Neuropathy\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 065554
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561347-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06561347)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Zanubrutinib\, Bendamust
 ine\, Rituximab Prev. Untreated WM\nEstimated primary completion: 1 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065613
 47
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421560-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04421560)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Pembrolizumab\, Ibruti
 nib and Rituximab in PCNSL\nEstimated primary completion: 5 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04421560
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475235-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06475235)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Pembrolizumab + Chemothe
 rapy in Newly Diagnosed PCNSL\nEstimated primary completion: 30 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06475235
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254560-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06254560)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab for Serious Ap
 lastic Anemia With Platelet Transfusion Refractoriness\nEstimated primary 
 completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06254560
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471738-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06471738)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Co
 mbination of Zanubrutinib\, Rituximab and Venetoclax in Patients With Prev
 iously Untreated Follicular Lymphoma\nEstimated primary completion: 30 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 71738
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06209619-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06209619)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06209619
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03361852-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT03361852)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Follicular Lymphoma.\nStudy: Pe
 rsonalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for F
 ollicular Lymphoma\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03361852
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676631-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06676631)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: NK010 or NK042 in Combin
 ation With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nep
 hritis\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06676631
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04161248-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04161248)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Phase I Master Protocol 
 of Novel Combination Therapy for Patients With Relapsed or Refractory Aggr
 essive B-Cell Lymphoma\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04161248
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06489808-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06489808)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Linperlisib Combined Wit
 h Immunochemotherapy in Relapsed/Refractory LBCL\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06489808
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362967-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06362967)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: The Efficacy and Safety 
 of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibod
 ies Prior to Allo-HSCT\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06362967
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115631-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04115631)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Comparison of Three Ch
 emotherapy Regimens for the Treatment of Patients With Newly Diagnosed Man
 tle Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04115631
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04216524)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Venetoclax\, SL-401\, an
 d Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Ne
 oplasm\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647732-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06647732)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Zanubrutinib Plus Rituxi
 mab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma
  (MALT)\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06647732
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02436707-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02436707)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Novel Combination Therap
 y in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02436707
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134284-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT06134284)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Clinical Study of OR for
  Second-line Treatment of Refractory MZL\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritux
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06134284
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05214183-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05214183)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Acalabrutinib and Rituxi
 mab in Elderly Patients With Untreated Mantle Cell Lymphoma\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05214183
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04679012-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04679012)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects Wi
 th Richter's Transformation\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04679012
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533164-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05533164)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Effect on Decr
 easing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experi
 encing a PMR Relapse\nEstimated primary completion: January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05533164
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03579875-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03579875)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Alpha/Beta TCD HCT in Pa
 tients With Inherited BMF Disorders\nEstimated primary completion: 1 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT035798
 75
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06572618-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06572618)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Nemtabrutinib With Ritux
 imab for the Treatment of Patients With Mantle Cell Lymphoma\nEstimated pr
 imary completion: 8 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06572618
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615974-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05615974)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Phase I/II Study of 
 LM-101 Injection in Patients With Advanced Malignant Tumors\nEstimated pri
 mary completion: 11 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05615974
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06573645-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06573645)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Phase III Clinical Tri
 al of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Tr
 eatment of Male Patient With Newly Diagnosed Advanced DLBCL\nEstimated pri
 mary completion: 12 January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06573645
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04978584)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and W
 ith Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germ
 inal Center Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated pr
 imary completion: 16 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04978584
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03267433-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03267433)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab With or Withou
 t Stem Cell Transplant in Treating Patients With Minimal Residual Disease-
 Negative Mantle Cell Lymphoma in First Complete Remission\nEstimated prima
 ry completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03267433
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583071-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05583071)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Methotrexate\, Tafasitam
 ab\, Lenalidomide and Rituximab in Patients With PCNSL\nEstimated primary 
 completion: February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05583071
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736419-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05736419)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Immune Suppre
 ssion Treatment for People With Sickle Cell Disease or β-Thalassemia Who 
 Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT
 )\nEstimated primary completion: 9 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05736419
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832267-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06832267)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Rituximab-Methotrexate-
 Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL\
 nEstimated primary completion: 13 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06832267
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03147612)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Low-Intensity Chemothera
 py\, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chr
 omosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia\nEst
 imated primary completion: 28 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522386-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06522386)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: GATE1: A Multicenter Pha
 se II Study of Pirtobrutinib\, Rituximab and Venetoclax Combination Therap
 y for Patients With Previously Untreated Mantle Cell Lymphoma\nEstimated p
 rimary completion: 28 February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06522386
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206823-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07206823)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Efficacy and Safety of 
 Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refra
 ctory Primary Immune Thrombocytopenia\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 206823
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362199-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07362199)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Anti-CD38 Monoclonal Ant
 ibody Combined With Rituximab in the Management of Primary Immune Thromboc
 ytopenia (ITP)\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07362199
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05249959-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05249959)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Consolidation With Lonca
 stuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treat
 ed (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.\nEst
 imated primary completion: March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05249959
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788964-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06788964)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Loncastuximab Tesirine a
 nd Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in 
 Patients With Large B-cell Lymphoma (CORAL)\nEstimated primary completion:
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 788964
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03295383-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03295383)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Randomized Clinical Tria
 l Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophospham
 ide in Severe Forms of Mucous Membrane Pemphigoid\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03295383
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06929624)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus
  R-GemOx in Diffuse Large B-cell Lymphoma\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0692
 9624
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04799275-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy
  in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell L
 ymphoma\nEstimated primary completion: 1 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07884708-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07884708)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Chidamide\, Lenalidomide
 \, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL\nEstimated prim
 ary completion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07884708
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04212013-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270318
DTEND;VALUE=DATE:20270319
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04212013)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Study of Ibrutinib Wit
 h Rituximab in People With Untreated Marginal Zone Lymphoma\nEstimated pri
 mary completion: 18 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04212013
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03710772)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Ibrutinib\, Rituximab\, 
 Venetoclax\, and Combination Chemotherapy in Treating Patients With Newly 
 Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 22 March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03710772
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05495464-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT05495464)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: A Pilot "Window-3" Study
  of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel The
 rapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05495464
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03929601-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03929601)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab-pvvr and Abata
 cept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03929601
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06611696-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT06611696)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Avacopan vs Reduced-dose
  Glucocorticoids in ANCA-associated Vasculitis\nEstimated primary completi
 on: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06611696
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05545384-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05545384)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Immediate Versus Delayed
  Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associate
 d Acute Demyelinating Syndromes in Children: a Randomized Controlled Clini
 cal Trial\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05545384
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270835-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07270835)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Zanubrutinib Combined Wi
 th Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07270835
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01829958-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT01829958)
DESCRIPTION:Rituxan (Rituximab)\, phase na\, Diffuse Large B-Cell Lymphoma.
 \nStudy: Comprehensive Geriatric Assessment to Predict Toxic Events in Old
 er Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Pha
 se Therapy\nEstimated primary completion: April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT01829958
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029139-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07029139)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study to Learn More Ab
 out the Effects and Safety of JMT601 in Adults With Primary Membranous Nep
 hropathy\nEstimated primary completion: 1 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07029139
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303792-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05303792)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Comparing Inotuzumab Com
 bined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemother
 apy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblasti
 c Leukemia\nEstimated primary completion: 1 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05303792
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Safety and Prelimina
 ry Efficacy Study of CC-99282\, Alone and in Combination With Anti-lymphom
 a Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas
  (R/R NHL)\nEstimated primary completion: 7 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954805-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06954805)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Defining ctDNA Metrics i
 n Posttransplant Lymphoproliferative Disorder (PTLD)\nEstimated primary co
 mpletion: 14 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06954805
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168161-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07168161)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: BDB-001 Phase III Trial 
 in ANCA-Associated Vasculitis\nEstimated primary completion: 16 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07168161
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03194815-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03194815)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: IVIG and Rituximab in An
 tibody-associated Psychosis - SINAPPS2\nEstimated primary completion: 30 A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0319
 4815
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942507-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06942507)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Zanubrutinib Combined W
 ith BR in the First-line Treatment of Waldenström's Macroglobulinemia\nEs
 timated primary completion: 30 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06942507
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03531736-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT03531736)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: T Cell Depleted Allogene
 ic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Inte
 nsity Regimen in Patients With Hematologic Malignancies and Aplastic Anemi
 a\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03531736
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05834855-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05834855)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Non-inferiority Study of
  Rituximab Compared to Ocrelizumab in Relapsing MS\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05834855
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072208-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07072208)
DESCRIPTION:Rituxan (Rituximab)\, phase na\, Diffuse Large B-Cell Lymphoma.
 \nStudy: Pomalidomide\, Rituximab and Orelabrutinib Combined With Polatuzu
 mab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBC
 L\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07072208
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769333-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07769333)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Rituximab With Corticost
 eroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pem
 phigus Vulgaris\nEstimated primary completion: 5 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07769333
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01473628-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT01473628)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade
  1 or Grade 2 Follicular Lymphoma\nEstimated primary completion: 20 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT01473628
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868395-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270524
DTEND;VALUE=DATE:20270525
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05868395)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Efficacy of Polatuzumab\
 , Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle 
 Cell Lymphoma\nEstimated primary completion: 24 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05868395
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04458610-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04458610)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Zanubrutinib and Rituximab for the Treatment of Previously Untreate
 d Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated pr
 imary completion: 26 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04458610
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788456-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07788456)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Multi-target Drugs Seque
 ntial Combination Therapy in Adults Patients With Newly Diagnosed Primary 
 Immune Thrombocytopenia\nEstimated primary completion: 30 May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07788456
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02727803-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02727803)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Personalized NK Cell The
 rapy in CBT\nEstimated primary completion: 31 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02727803
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04416451-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04416451)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Phase II Study Using R
 ituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymp
 homa\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04416451
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03206671-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03206671)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Treatment Protocol of th
 e NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma
  and Leukemia in Children and Adolescents\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03206
 671
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05578976)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC
 ) Epcoritamab Combined With Intravenous and Oral Rituximab\, Cyclophospham
 ide\, Doxorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or
  R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Ly
 mphoma (DLBCL)\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834373-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06834373)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refr
 actory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy\nE
 stimated primary completion: 10 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06834373
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03697512-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03697512)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: MALIBU Trial - Combinati
 on of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas\nEstima
 ted primary completion: 15 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03697512
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478472-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270623
DTEND;VALUE=DATE:20270624
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06478472)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Prospective Clinical St
 udy of Orelabrutinib in Combination With Rituximab (OR) for Primary Margin
 al Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy\nEsti
 mated primary completion: 23 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06478472
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523975-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270624
DTEND;VALUE=DATE:20270625
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03523975)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Venetoclax\, Lenalidom
 ide and Rituximab in Patients With Previously Untreated Mantle Cell Lympho
 ma\nEstimated primary completion: 24 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03523975
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351527-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06351527)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Evaluate the Safety\, To
 lerability\, Pharmacokinetics\, and Preliminary Efficacy of ICP-248 as Mon
 otherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-
 cell Malignancies\nEstimated primary completion: 25 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06351527
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251180-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06251180)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Phase Ib Study of Rocbru
 tinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell N
 on-Hodgkin Lymphoma\nEstimated primary completion: 30 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06251180
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03321643-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT03321643)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Testing the Addition of an Immunotherapy Agent\, Atezolizumab\, Wh
 en Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Pl
 us Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Bac
 k or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
 \nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03321643
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00412594-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT00412594)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Cladribine and Rituximab
  in Treating Patients With Hairy Cell Leukemia\nEstimated primary completi
 on: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT00412594
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02427620-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02427620)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Ibrutinib\, Rituximab\, 
 and Consolidation Chemotherapy in Treating Young Patients With Newly Diagn
 osed Mantle Cell Lymphoma\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02427620
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04759586-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04759586)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Nivolumab in Combination
  With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Med
 iastinal B-Cell Lymphoma\nEstimated primary completion: 30 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04759586
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071246-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07071246)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Rituximab for the Treat
 ment of New-onset AChR-Myasthenia Gravis\nEstimated primary completion: 30
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 71246
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581562-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06581562)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Rheumatoid Arthritis.\nStudy: O
 pen-label Single-Center Study to Evaluate the Safety and Efficacy of Combi
 ning Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.\nEstim
 ated primary completion: July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06581562
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614282-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07614282)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Rituximab for PTLD Preve
 ntion in Solid Organ Transplant Recipients With EBV DNAemia\nEstimated pri
 mary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07614282
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504940-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06504940)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Optimize Study - Orelabr
 utinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)\nEstim
 ated primary completion: 8 July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06504940
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703657-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07703657)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: A Randomized Controlled
  Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAe
 mia After Allogeneic Hematopoietic Stem Cell Transplantation\nEstimated pr
 imary completion: 9 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07703657
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496308-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06496308)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Bendamustine and Rituxim
 ab With or Without Orelabrutinib in MCL Treatment\nEstimated primary compl
 etion: 10 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06496308
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073833-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07073833)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: The Safety\, Tolerabilit
 y\, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell No
 n Hodgkin Lymphoma\nEstimated primary completion: 30 July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07073833
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04022239-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04022239)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Bendamustine With or W
 ithout Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cel
 l Transplant\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04022239
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594798-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04594798)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Polatuzumab V
 edotin\, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL\nE
 stimated primary completion: 31 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04594798
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265220-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06265220)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: AB-101 in Combination Wi
 th B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or 
 IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematos
 us\nEstimated primary completion: August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06265220
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04609046-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04609046)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Testing the Addition of Lenalidomide and Nivolumab to the Usual Tr
 eatment for Primary CNS Lymphoma\nEstimated primary completion: 1 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04609046
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159906-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07159906)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Homoharringtonine\, BCL-2 Inhibitor\, Rituximab\, and Prednisone
  in Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary c
 ompletion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07159906
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998669-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04998669)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Lo
 ncastuximab Tesirine in Combination With Rituximab in Patients With Relaps
 ed or Refractory Follicular Lymphoma\nEstimated primary completion: 1 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049986
 69
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03136146-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03136146)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Combination Chemotherapy
  in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leuk
 emia\, Lymphoblastic Lymphoma\, Burkitt Lymphoma/Leukemia\, or Double-Hit 
 Lymphoma/Leukemia\nEstimated primary completion: 1 August 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03136146
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745949-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04745949)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: PACIFIC: Primary Mediast
 inal Large B-cell Lymphoma Treated With Antibody Therapy\, Checkpoint Inhi
 bitor in Frontline With ImmunoChemotherapy\nEstimated primary completion: 
 3 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04745949
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02337985-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT02337985)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Gene Therapy and Combination Chemotherapy in Treating Patients Wit
 h AIDS-Related Non-Hodgkin Lymphoma\nEstimated primary completion: 9 Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0233798
 5
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697339-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07697339)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: HDM2005 Combination Ther
 apy in Relapsed/Refractory Mantle Cell Lymphoma\nEstimated primary complet
 ion: 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07697339
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844061-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03844061)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Belimumab and Rituximab 
 Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclero
 sis\nEstimated primary completion: 30 August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03844061
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subj
 ects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-
 NHL)\nEstimated primary completion: September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444710-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07444710)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Testing the Addition of 
 an Anti-Cancer Drug\, Glofitamab\, to the Usual Chemotherapy Treatment (Al
 ternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma\nEs
 timated primary completion: 1 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07444710
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With St
 andard of Care in Participants With Relapsed or Refractory Diffuse Large B
 -Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05139017
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557330-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06557330)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: MRD Guided De-intensific
 ation of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma\nEstimat
 ed primary completion: 29 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06557330
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03571568-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03571568)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study of BI-1206 in 
 Combination With Rituximab With or Without Acalabrutinib in Subjects With 
 Indolent B-Cell NHL\nEstimated primary completion: 30 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03571568
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638787-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07638787)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Pola-R-CHP Plus Sonrot
 oclax in Untreated BCL2-High/Double-Hit LBCL\nEstimated primary completion
 : 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07638787
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Safety and Efficacy Trial of Epcoritamab Combinations in Subject
 s With B-cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 
 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04663347
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683171-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05683171)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 A Phase 1/2\, Open-label Study of Valemetostat in Combination With Rituxim
 ab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05683171
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201248-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05201248)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Evaluate Ad
 verse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritam
 ab As Monotherapy or Combined With Standard of Care Therapies in Adult Par
 ticipants in China With B-Cell Non-Hodgkin Lymphoma\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05201248
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714838-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06714838)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Induced Remiss
 ion in Patients With Chronic Inflammatory Demyelinating Polyneuropathy\nEs
 timated primary completion: October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06714838
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06064344-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271006
DTEND;VALUE=DATE:20271007
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06064344)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: RCT of Intralesional Ri
 tuximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal
  MALT Lymphoma\nEstimated primary completion: 6 October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06064344
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04002947-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04002947)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated 
 Diffuse Large B-cell Lymphoma\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04002947
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124936-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271026
DTEND;VALUE=DATE:20271027
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07124936)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of HDM2005 in Combination With Standard of Care in Patie
 nts With Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 26 O
 ctober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 124936
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Assess BMS-
 986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refr
 actory Non-Hodgkin Lymphomas\nEstimated primary completion: 28 October 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06090539
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973811-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06973811)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: ZR-MTX for PIOL Phase II
  Trial\nEstimated primary completion: 30 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06973811
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389356-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07389356)
DESCRIPTION:Rituxan (Rituximab)\, phase na\, Diffuse Large B-Cell Lymphoma.
 \nStudy: Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of 
 Late Relapsed DLBCL\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07389356
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT01424982)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Combination Chemotherapy
  and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic
  Leukemia\nEstimated primary completion: 31 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT01424982
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980584-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06980584)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Study on the Treatment 
 of Nonthrombotic Obstructive Pulmonary Hypertension\nEstimated primary com
 pletion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06980584
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03684980-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT03684980)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: LTA Pilot Study of Gluca
 rpidase in Patients With Central Nervous System Lymphoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03684980
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05211401-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05211401)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab in Patients Wi
 th ST-elevation Myocardial Infarction\nEstimated primary completion: Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05211
 401
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136351-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06136351)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of the Zanubruti
 nib Given in Combination With Bendamustine and Rituximab in (Elderly or TP
 53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed 
 Mantle Cell Lymphoma\nEstimated primary completion: 1 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06136351
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03150693-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03150693)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Inotuzumab Ozogamicin an
 d Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B A
 cute Lymphoblastic Leukemia\nEstimated primary completion: 1 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03150693
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001540-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07001540)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combi
 ned With Rituximab\, Gemcitabine\, and Oxaliplatin (Pola-R-GemOx) as Salva
 ge Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) P
 atients Ineligible for Autologous Transplantation\nEstimated primary compl
 etion: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07001540
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735717-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05735717)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: MT2021-08T Cell Receptor
  Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies\nEstimate
 d primary completion: 30 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05735717
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225439-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07225439)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Ce
 lls for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
  (NHL)\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07225439
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03500731-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03500731)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Lung and Bone Marrow T
 ransplantation for Lung and Bone Marrow Failure\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03500731
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784052-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04784052)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Depleted Donor Stem Ce
 ll Transplant in Children and Adults With Fanconi Anemia After Being Condi
 tioned With a Regimen Containing Briquilimab\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04784052
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Safety and Efficacy Study of Epcoritamab in Subjects With Relapse
 d/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimate
 d primary completion: December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477366-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07477366)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Study of CD19 t-haNK and
  NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07477366
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756308-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06756308)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Enasidenib in
  People With T-Cell Lymphoma\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06756308
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136976-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05136976)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Rituximab Therapy in Ant
 i-Myelin Associated Glycoprotein Patients With Characteristics of Good Res
 ponders\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05136976
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745728-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04745728)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Different Immunosuppress
 ive Treatment in iMN\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04745728
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06003283-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT06003283)
DESCRIPTION:Rituxan (Rituximab)\, phase 4\, Rheumatoid Arthritis.\nStudy: T
 apering of Rituximab Based on Interval Prolongation Compared to Disease Ac
 tivity-guided Dose Reduction in Patients With Rheumatoid Arthritis\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06003283
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269639-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07269639)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Golcadomide\, Poseltinib\, and Rituximab for Relapsed/Refractory
  Diffuse Large B-cell Lymphoma\nEstimated primary completion: 1 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07269639
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946407-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06946407)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Rituximab\, Methotrexat
 e\, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidat
 ion in Primary Central Nervous System Lymphoma\nEstimated primary completi
 on: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06946407
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04872790-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04872790)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Venetoclax\, Dasatinib\,
  Prednisone\, Rituximab and Blinatumomab for the Treatment of Newly Diagno
 sed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leuke
 mia or Mixed Phenotype Acute Leukemia\nEstimated primary completion: 2 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 72790
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890884-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06890884)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab 
 Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) Versus Polatu
 zumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLB
 CL) (MK-2140-011/waveLINE-011)\nEstimated primary completion: 13 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06890884
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07034508-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07034508)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab
  Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1\nEstimated pri
 mary completion: 20 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07034508
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Inotuzumab Ozogamicin 
 and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic
  Leukemia\nEstimated primary completion: 25 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01371630
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742502-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06742502)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated 
 PMBL\nEstimated primary completion: 30 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06742502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405255-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07405255)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Zillion: Zanubrutinib Co
 mbined With Chemotherapy for Newly Diagnosed CNS Lymphoma\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07405255
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03474744-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03474744)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Copanlisib and Rituximab
  in Marginal Zone Lymphoma Patients\nEstimated primary completion: 30 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0347
 4744
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441097-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06441097)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06441097
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07041268-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07041268)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Immunotherapy of the Rec
 ent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituxima
 b\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07041268
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247383-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07247383)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Orelabrutinib Plus Low-D
 ose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07247383
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07418190)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ef
 ficacy and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²) in
  Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786040-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05786040)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Tafasitamab and Rituxima
 b for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05786040
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538180-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07538180)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Serplulimab\, Chidamide\
 , and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly 
 MYC/BCL2 Double-Expressor DLBCL\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07538180
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645718-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05645718)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Study of Pedi-cRIB: Mini
 -Hyper-CVD With Condensed Rituximab\, Inotuzumab Ozogamicin and Blinatumom
 ab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lym
 phocytic Leukemia\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05645718
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00977977-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT00977977)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab Plus Cyclospor
 ine in Idiopathic Membranous Nephropathy\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritux
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T00977977
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Immunosuppressant Manage
 ment in Rheumatology Patients Undergoing Elective Total Shoulder Arthropla
 sty\nEstimated primary completion: January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765317-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06765317)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Glofitamab-based Treatment in People With Diffuse Large
  B-cell Lymphoma\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06765317
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448324-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07448324)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Orelabrutinib Combined W
 ith Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for U
 ntreated MZL\nEstimated primary completion: 1 January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07448324
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788081-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05788081)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Tr
 eatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide\, R
 ituximab +/- Nivolumab.\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05788081
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015242-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280109
DTEND;VALUE=DATE:20280110
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07015242)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of the Efficacy 
 and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in
  Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
 \nEstimated primary completion: 9 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07015242
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051915-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07051915)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: The Holistic Study\nEsti
 mated primary completion: 31 January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07051915
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05783609-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05783609)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ep
 coritamab and Rituximab for First-line Follicular Lymphoma\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05783609
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06983821-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06983821)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Safe Effective Therapy W
 ith Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)\nEsti
 mated primary completion: February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06983821
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099471-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05099471)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Efficacy of Venetoclax i
 n Combination With Rituximab in Waldenström's Macroglobulinemia\nEstimate
 d primary completion: March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05099471
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06508658)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidom
 ide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
 ed Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relap
 sed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06508658
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404088-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04404088)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ac
 alabrutinib\, Lenalidomide\, and Rituximab for the Treatment of CD20 Posit
 ive Stage III-IV\, Grade 1-3a Follicular Lymphoma\nEstimated primary compl
 etion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04404088
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: ALX148\, Rituximab and Lenalidomide for the Treatment of Indolen
 t and Aggressive B-cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : 21 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05025800
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550855-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07550855)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: So
 nrotoclax\, Zanubrutinib and Rituximab in Previously Untreated Patients Wi
 th Follicular Lymphoma\nEstimated primary completion: 30 March 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07550855
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04840602-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04840602)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Testing the Combination 
 of Venetoclax and Rituximab\, in Comparison to the Usual Treatment (Ibruti
 nib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobuline
 mia/Lymphoplasmacytic Lymphoma\nEstimated primary completion: 31 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04840602
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415980-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07415980)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Phase Ib/II Study of P
 olatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Di
 agnosed Elderly Patients With Double-Expressor DLBCL\nEstimated primary co
 mpletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07415980
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04323566-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04323566)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab Treatment for 
 Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System
  Involvement\nEstimated primary completion: 1 April 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04323566
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231952-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280411
DTEND;VALUE=DATE:20280412
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07231952)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Pirtobrutinib
 \, Venetoclax\, and Rituximab in People With Waldenström's Macroglobuline
 mia (WM)/Lymphoplasmacytic Lymphoma (LPL)\nEstimated primary completion: 1
 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7231952
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06911502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: A 
 Study to Compare the Efficacy and Safety of Golcadomide in Combination Wit
 h Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela
 psed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Lin
 e of Systemic Therapy (GOLSEEK-4)\nEstimated primary completion: 24 April 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541665-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06541665)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Phase I Study Evaluating
  Tolerability\, Safety\, Pharmacokinetics\, and Efficacy of Combined ONO-4
 059 and R-MPV Therapy for PCNSL\nEstimated primary completion: 28 April 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06541665
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803693-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06803693)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06803693
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601607-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07601607)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refracto
 ry Diffuse Large B-cell Lymphoma\nEstimated primary completion: 30 May 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07601607
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05998642-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05998642)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Ibrutinib Combination Th
 erapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CN
 S Lymphoma\nEstimated primary completion: 31 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05998642
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952413-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06952413)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Study of the Efficacy an
 d Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndro
 me (ME/CFS)\nEstimated primary completion: 31 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06952413
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06342544-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06342544)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Immediate Corticosteroid
  Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a P
 ROBE Multicenter Open-label Randomized Controlled Trial.\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06342544
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931368-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT04931368)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: OptiMATe: De-escalated I
 nduction Treatment in Primary CNS Lymphoma\nEstimated primary completion: 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0493
 1368
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05389423-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT05389423)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Pomalidomide and Dose-Ad
 justed EPOCH +/- Rituximab for HIV-Associated Lymphomas\nEstimated primary
  completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05389423
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432022-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07432022)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Phase I/II Study to 
 Evaluate the Safety\, Tolerability\, and Preliminary Efficacy of the EMB-0
 7 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymph
 oma\nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07432022
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259122-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07259122)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Phase II Clinical Stud
 y of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody an
 d Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Mac
 roglobulinemia\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07259122
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01446133-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT01446133)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Le
 ukemia/Small Lymphocytic Lymphoma (CLL-SLL)\nEstimated primary completion:
  30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 01446133
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899337-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03899337)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Trial of CHOP-R Therap
 y\, With or Without Acalabrutinib\, in Patients With Newly Diagnosed Richt
 er's Syndrome\nEstimated primary completion: 30 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03899337
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02007044-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02007044)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Ibrutinib With or Without Rituximab in Treating Patients With Relap
 sed Chronic Lymphocytic Leukemia\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02007044
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05914155-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05914155)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Clinical Study of Rituxi
 mab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic
  Syndrome\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05914155
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05058404-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05058404)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: Sh
 ortened vs Standard Chemotherapy Combined With Immunotherapy for the Initi
 al Treatment of Patients With High Tumor Burden Follicular Lymphoma\nEstim
 ated primary completion: July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05058404
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760610-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07760610)
DESCRIPTION:Rituxan (Rituximab)\, phase 4\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly D
 iagnosed DLBCL After First-Line Response\nEstimated primary completion: Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077606
 10
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT06031233)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Evaluating the Safety of
  Shortened Infusion Times for dIfferent Oncological Immunotherapie\nEstima
 ted primary completion: July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06031233
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199296-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07199296)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Orelabrutinib and Rituxi
 mab With Optional Autologous Hematopoietic Stem Cell Transplantation in MC
 L Treatment\nEstimated primary completion: 1 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07199296
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06905509)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and 
 Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or 
 Refractory Large B-cell Lymphoma\nEstimated primary completion: 1 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549231-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280708
DTEND;VALUE=DATE:20280709
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06549231)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Evaluation of Efficacy a
 nd Safety of Rituximab and Mycophenolate Mofetil Combination in Patients W
 ith Interstitial Lung Disease Related to Systemic Sclerosis\nEstimated pri
 mary completion: 8 July 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06549231
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397832-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07397832)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: CRP Regimen in Treating Elderly Patients With Previously Untreated
  Double-Positive DLBCL\nEstimated primary completion: 30 July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07397832
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04196413-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04196413)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: GD2 CAR T Cells in Diffu
 se Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)\n
 Estimated primary completion: 31 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04196413
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224100-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07224100)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Dose-Adjusted EPOCH With
  or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed 
 Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma\nEs
 timated primary completion: 31 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07224100
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045247-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06045247)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CV
 P for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patient
 s With Newly Diagnosed Diffuse Large B-cell Lymphoma\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06045247
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01880567-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT01880567)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Ibrutinib and Rituximab 
 in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or O
 lder Patients With Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary
  completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT01880567
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764601-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07764601)
DESCRIPTION:Rituxan (Rituximab)\, phase na\, Diffuse Large B-Cell Lymphoma.
 \nStudy: R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma\nEs
 timated primary completion: August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07764601
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694414-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07694414)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Rituximab for Treatment 
 of Checkpoint Inhibitor Induced Immune-related Adverse Events\nEstimated p
 rimary completion: 1 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07694414
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03653338-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03653338)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: T-Cell Depleted Altern
 ative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other
  Anemias\nEstimated primary completion: 1 August 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03653338
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03630211-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03630211)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Autologous Stem Cell Tra
 nsplantation in Patients With Systemic Sclerosis\nEstimated primary comple
 tion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03630211
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Chronic Lymphocytic Leukemia.\n
 Study: Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants
  With Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mant
 le Cell Lymphoma\nEstimated primary completion: 1 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03984448-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT03984448)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing the Addition of a New Anti-cancer Drug\, Venetoclax\, to
  Usual Chemotherapy for High Grade B-cell Lymphomas\nEstimated primary com
 pletion: 13 August 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03984448
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765111-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04765111)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Acalabrutinib and Rituxi
 mab for the Treatment of Previously Untreated Mantle Cell Lymphoma\nEstima
 ted primary completion: 30 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04765111
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308132-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07308132)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: A Study of JNJ-95566692 
 in Participants With Non-Hodgkin Lymphoid Malignancies\nEstimated primary 
 completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07308132
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07588698)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab in Combination With R-CHOP for Patients With Aggressiv
 e Non-Hodgkin Lymphoma\nEstimated primary completion: 31 August 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082102-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06082102)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Efficacy and Safety of O
 relabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rit
 uximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma\nEstima
 ted primary completion: 31 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06082102
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226843-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07226843)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Follicular Lymphoma.\nStudy: A 
 Study of LY4584180 in Adult Participants With Previously Treated Blood Can
 cers\nEstimated primary completion: September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07226843
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169565-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07169565)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Ibrutinib Followed by BR
  (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström M
 acroglobulinemia\nEstimated primary completion: 1 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07169565
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272499-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07272499)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Orelabrutinib Plus Lisaf
 toclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Dise
 ase\nEstimated primary completion: 10 September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07272499
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255963-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07255963)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Pirtobrutinib\, Lisaftoclax\, and Rituximab in the Treatment of R/
 R DLBCL\nEstimated primary completion: 30 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07255963
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185373-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT07185373)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3.\nStudy: Orelabrutinib Combined
  With Teniposide\, Rituximab and Methotrexate for Newly Diagnosed PCNSL\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07185373
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635162-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05635162)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Zanubrutinib Plus Rituxi
 mab for Patients With Indolent Mantle Cell Lymphoma\nEstimated primary com
 pletion: October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05635162
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510309-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06510309)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab Plus Venetocla
 x in Front Line Marginal Zone Lymphoma\nEstimated primary completion: Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06510
 309
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644183-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06644183)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractor
 y/Relapsed Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completio
 n: 1 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06644183
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06516978)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RC
 HOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL\nEstimated
  primary completion: 1 October 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06516978
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00092222-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT00092222)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Virotherapy and Natural 
 History Study of KHSV-Associated Multricentric Castleman s Disease With Co
 rrelates of Disease Activity\nEstimated primary completion: 1 October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT00092222
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951959-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05951959)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Acalabrutinib
  Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantl
 e Cell Lymphoma\nEstimated primary completion: 31 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05951959
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234019-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07234019)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab Combining Anti
 -CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Im
 mune Thrombocytopenia (ITP)\nEstimated primary completion: November 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07234019
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT02877303)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Blinatumomab\, Inotuzuma
 b Ozogamicin\, and Combination Chemotherapy as Frontline Therapy in Treati
 ng Patients With B Acute Lymphoblastic Leukemia\nEstimated primary complet
 ion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02877303
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04627753-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04627753)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Study of Lenalidomide/Ri
 tuximab Maintenance for Transplantation Ineligible Patients With PCNSL.\nE
 stimated primary completion: 2 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04627753
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07335562)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Study to Compare the E
 fficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel)\, 
 CD19-CAR T Cells\, Versus Standard of Care in Participants With Active Sys
 temic Sclerosis\nEstimated primary completion: 14 November 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07335562
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257055-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07257055)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Phase 2 Study of BTKi-Ri
 tuximab Induction Followed by Glofitamab Consolidation in High Risk Untrea
 ted MCL Patients - WINDOW-4 Study\nEstimated primary completion: 24 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072570
 55
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818499-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07818499)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of BL-M08D1 in Combination With Immunochemotherapy in Pa
 tients With Diffuse Large B-Cell Lymphoma\nEstimated primary completion: D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7818499
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884035-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04884035)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Study of Safety and Effi
 cacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lym
 phoma\nEstimated primary completion: 1 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04884035
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649304-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07649304)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: AMC 120\, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HI
 V-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")\nEstimated p
 rimary completion: 1 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07649304
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07938619)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Tafasitamab\, Lenalidomide\, Rituximab\, and Orelabrutinib for Pat
 ients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated
  primary completion: 1 December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944651-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281208
DTEND;VALUE=DATE:20281209
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07944651)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Pirtobrutinib With Sonro
 toclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphom
 a Following Covalent BTK-Inhibitor Failure\nEstimated primary completion: 
 8 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07944651
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220032-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06220032)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexra
 zoxane in Patients With Diffuse Large-B Cell Lymphoma\nEstimated primary c
 ompletion: 15 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06220032
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002099-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07002099)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Selinexor\, High-dose Me
 thotrexate\, and Rituximab Combined With Radiotherapy for Newly Diagnosed\
 , Transplant-ineligible Patients With Central Nervous System Lymphoma: An 
 Open-label\, Single-arm\, Multicenter Phase II Study\nEstimated primary co
 mpletion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07002099
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410520-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07410520)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: PD-1 Inhibitor Combined 
 With Rituximab\, Methotrexate\, and Orelabrutinib (PD-1i+RMO) for Newly Di
 agnosed PCNSL and SCNSL.\nEstimated primary completion: 31 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07410520
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350850-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07350850)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Multicenter\, Prospect
 ive Clinical Trial With a Concurrent Control Evaluating Methotrexate Combi
 ned With Rituximab\,Sintilimab and Pirtobrutinib vs. Investigator-Selected
  Standard of Care in Treatment-Naive PCNSL\nEstimated primary completion: 
 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07350850
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01419561-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT01419561)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Natural History Study of
  the KSHV Inflammatory Cytokine Syndrome (KICS)\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT01419561
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792253-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06792253)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study Comparing BEBT-908 Combined With R to SOC for the Treatment 
 of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary co
 mpletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06792253
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05207358-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT05207358)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Minimizing Glucocorticoi
 d Administration in Patients With Proliferative Lupus Nephritis\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05207358
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675291-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07675291)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Rituximab Combining Wit
 h Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Child
 ren\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07675291
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693881-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07693881)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Prevention of Epstein-B
 arr Virus Reactivation With the ATG-based Haploidentical Protocol Combined
  With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell 
 Transplantation\nEstimated primary completion: 31 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07693881
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04540380-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04540380)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Renal Allograft Toleranc
 e Through Mixed Chimerism - SMC/MGH\nEstimated primary completion: January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04540380
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691606-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07691606)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: A Study of ARC-02 in B-c
 ell NHL\nEstimated primary completion: January 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07691606
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04518475-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290210
DTEND;VALUE=DATE:20290211
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT04518475)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Eltrombopag Combining Ri
 tuximab Versus Eltrombopag in the Management of Primary Immune Thrombocyto
 penia (ITP) in Adults\nEstimated primary completion: 10 February 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04518475
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350318-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06350318)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ri
 tuximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas\nEstim
 ated primary completion: March 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06350318
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918431-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06918431)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Asparaginase Erwinia Chr
 ysanthemi With Chemotherapy for the Treatment of High-Risk Adults With New
 ly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\nEstim
 ated primary completion: 30 March 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06918431
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608731-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07608731)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Golcadomide With Pemetre
 xed\, Rituximab\, and Dexamethasone for Relapsed and Refractory CNS Lympho
 mas\nEstimated primary completion: April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07608731
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188676-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06188676)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Nivolumab 40 mg in Combi
 nation With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-
 Cell Lymphoma\nEstimated primary completion: 1 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06188676
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952024-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290422
DTEND;VALUE=DATE:20290423
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05952024)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or F
 rail Patients With DLBCL\nEstimated primary completion: 22 April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05952024
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406401-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290426
DTEND;VALUE=DATE:20290427
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05406401)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cycl
 ophosphamide\, Doxorubicin\, and Prednisone Plus Rituximab or Rituximab Bi
 osimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymph
 oma (DLBCL) (MK-2140-007)\nEstimated primary completion: 26 April 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05406401
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04669171-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04669171)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 A Novel Vaccine (EO2463) as Monotherapy and in Combination\, for Treatment
  of Patients With Indolent Non-Hodgkin Lymphoma\nEstimated primary complet
 ion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04669171
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594899-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07594899)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: AI-Driven Treatment Stra
 tegy vs Pola-R-CHP in Untreated LBCL\nEstimated primary completion: 31 May
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594899
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717177-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07717177)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: AI-Driven Treatment Stra
 tegy vs ZR2 in Older Treatment-naive Patients With LBCL\nEstimated primary
  completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07717177
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364423-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06364423)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leuk
 emias\nEstimated primary completion: 1 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06364423
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06717347)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination Wit
 h Rituximab Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) V
 ersus Rituximab Plus Cyclophosphamide\, Doxorubicin\, Vincristine\, and Pr
 ednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140
 -010)\nEstimated primary completion: 2 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06717347
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06792825)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: HM
 2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment
 -naive FL and MZL\nEstimated primary completion: 8 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04318678-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT04318678)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: CD123-Directed T-Cell Th
 erapy for Acute Myelogenous Leukemia (CATCHAML)\nEstimated primary complet
 ion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04318678
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643038-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07643038)
DESCRIPTION:Rituxan (Rituximab)\, phase 4\, Rheumatoid Arthritis.\nStudy: T
 reatment Strategy for Patients With RA-ILD\nEstimated primary completion: 
 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7643038
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464210-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07464210)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Nemtabrutinib\, Bortezom
 ib\, and Rituximab for WM\nEstimated primary completion: 1 August 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07464210
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908888-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07908888)
DESCRIPTION:Rituxan (Rituximab)\, phase 4\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Efficacy and Safety of Polatuzumab Vedotin\, Rituximab Combined Wi
 th Reduced-dose Cyclophosphamide\, Doxorubicin and Prednisone Regimen in t
 he Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Mul
 ticenter\, Single-arm\, Prospective Study\nEstimated primary completion: 1
 5 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07908888
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943872-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06943872)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Chronic Lymphocytic Leukemia.\n
 Study: A Study to Investigate Progression-Free Survival With Sonrotoclax P
 lus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Pl
 us Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic
  Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)\nEstima
 ted primary completion: 30 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06943872
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855016-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291010
DTEND;VALUE=DATE:20291011
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07855016)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Phase II Study of TT-0
 1488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in 
 Patients With Mantle Cell Lymphoma\nEstimated primary completion: 10 Octob
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078550
 16
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365306-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07365306)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab\, Rituximab\, Gemcitabine and Oxaliplatin (R-GemOx) as
  Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment 
 of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary co
 mpletion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07365306
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811557-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07811557)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Single-cell RNA Sequenc
 ing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of 
 Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Tre
 ated With Rituximab\nEstimated primary completion: 31 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07811557
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607549-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06607549)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Loncastuximab Tesirine a
 nd Rituximab Following Stereotactic Radiosurgery in Patients With Central 
 Nervous System Lymphomas (SOLAR)\nEstimated primary completion: November 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06607549
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854003-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06854003)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: BRAZAN: A Randomized Pha
 se 2 Study of Bendamustine\, Rituximab\, Cytarabine (AraC) Induction With 
 Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax M
 aintenance in Treatment-Naïve Mantle Cell Lymphoma\nEstimated primary com
 pletion: 1 November 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06854003
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Evaluate Gl
 ofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and 
 Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgki
 n Lymphoma\nEstimated primary completion: 30 November 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664411-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06664411)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Pola-ZR2P in Previously Untreated DLBCL\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06664411
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05409066)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: St
 udy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab 
 and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease 
 Activity in Adult Participants With Follicular Lymphoma\nEstimated primary
  completion: December 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05409066
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04989491-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT04989491)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Evaluation of the Effica
 cy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Preve
 ntion of the Epstein Barr Virus (EBV) Primary Infection and Post-transplan
 t Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Rece
 ived an EBV Seropositive Kidney Allograft\nEstimated primary completion: 1
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritux
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04989491
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493148-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07493148)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 
 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL\nEstimated primary 
 completion: 30 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07493148
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890585-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06890585)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Zanubrutinib\, Chidamide\, and Rituximab Induction With or Without
  CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL\nEstimated p
 rimary completion: 31 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06890585
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05245656-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05245656)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study Comparing Rituxi
 mab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC)
  With RB Therapy in Elderly Patients With Mentle Cell Lymphoma\nEstimated 
 primary completion: 31 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05245656
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06190301-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT06190301)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: RCT on Intralesional Ri
 tuximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma\nEstimated p
 rimary completion: 31 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06190301
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03952637-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT03952637)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Phase 1/2 Study of I
 ntravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galacto
 sidase in Type I and Type II GM1 Gangliosidosis\nEstimated primary complet
 ion: 1 January 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03952637
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902492-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07902492)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Efficacy of Rituximab fo
 r Remission Maintenance in Patients With Primary Angiitis of the Central N
 ervous System: an Open-label\, Randomized\, Controlled Trial Comparing Sys
 tematic Rituximab Infusions and Azathioprine\nEstimated primary completion
 : 1 January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07902492
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451847-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT07451847)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Comparison of a Strategy
  Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treat
 ment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and
  Microscopic Polyangiitis.\nEstimated primary completion: February 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07451847
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336395-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06336395)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Ma-Spore ALL 2020 Study\
 nEstimated primary completion: March 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06336395
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061512-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04061512)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3.\nStudy: Rituximab and Ibrutini
 b (RI) Versus Dexamethasone\, Rituximab and Cyclophosphamide (DRC) as Init
 ial Therapy for Waldenström's Macroglobulinaemia\nEstimated primary compl
 etion: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04061512
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965114-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06965114)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Testing the Combinatio
 n of Anti-cancer Drugs\, Tovorafenib Plus Rituximab\, in Patients With Hai
 ry Cell Leukemia\nEstimated primary completion: 1 March 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06965114
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06563596)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ep
 co\, Zanu\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06563596
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835530-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06835530)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Combination of Rituxim
 ab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffus
 e Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric
  Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FI
 L)\nEstimated primary completion: April 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06835530
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578077-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300421
DTEND;VALUE=DATE:20300422
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07578077)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Golcadomide in Combina
 tion With Rituximab for the Treatment of Patients With Relapsed or Refract
 ory Mantle Cell Lymphoma\nEstimated primary completion: 21 April 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07578077
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730542-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06730542)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Zanubrutinib in Combinat
 ion With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary 
 CNS Lymphoma\nEstimated primary completion: 30 April 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06730542
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827742-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07827742)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab vs Placebo for
  Maintenance in Systemic Sclerosis - Interstitial Lung Disease\nEstimated 
 primary completion: May 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07827742
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study of AZD0486 Mon
 otherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell
  Malignancies\nEstimated primary completion: 20 May 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097363-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07097363)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab With Dose Adjusted Etoposide\, Cyclophosphamide\, Vinc
 ristine\, Doxorubicin\, Prednisone and Rituximab (EPOCH-R) for the Treatme
 nt of Aggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : 31 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07097363
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03394365-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03394365)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Phase 3 Study of Tabel
 ecleucel for Participants With Epstein-Barr Virus-Associated Post-Transpla
 nt Lymphoproliferative Disease After Failure With Rituximab or Rituximab a
 nd Chemotherapy\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03394365
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573436-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07573436)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Loncastuximab Tesirine
  and Rituximab as First-line Therapy in Patients With Post-transplant Lymp
 hoproliferative Disorder (PLUTO)\nEstimated primary completion: June 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07573436
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654465-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07654465)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab Maintenance Ve
 rsus Observation After R2 Induction in Previously Untreated Marginal Zone 
 Lymphoma\nEstimated primary completion: July 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07654465
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137481-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07137481)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Phase II Study of CD5 CA
 R Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction Wi
 th Lymphodepleting Chemotherapy for the Management of Aggressive T Cell He
 matological Malignancies\nEstimated primary completion: 31 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07137481
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911553-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07911553)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Study to Evaluate Suro
 vatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age Wi
 th Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5\nEstim
 ated primary completion: 2 September 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07911553
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583810-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300925
DTEND;VALUE=DATE:20300926
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07583810)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Non-covalent BTK Inhibit
 or Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituxima
 b for the Treatment of Marginal Zone Lymphoma\nEstimated primary completio
 n: 25 September 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07583810
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674745-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07674745)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Autoantibody Reduction T
 herapy for Progressive Idiopathic Pulmonary Fibrosis\nEstimated primary co
 mpletion: 30 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07674745
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714421-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20301008
DTEND;VALUE=DATE:20301009
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT07714421)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large
  B Cell Lymphoma in Elderly or Unfit Patients\nEstimated primary completio
 n: 8 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07714421
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731789-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07731789)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ta
 fasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Ly
 mphoma\nEstimated primary completion: 31 October 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07731789
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972069-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06972069)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Tolerance Through Mixed 
 Chimerism (Sip-Tego)\nEstimated primary completion: 31 December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06972069
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831395-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07831395)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Rituximab\, Pirtobrutini
 b\, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transf
 ormed From CLL\nEstimated primary completion: 31 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07831395
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222631-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07222631)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: SB-4826 in Adult Parti
 cipants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Ly
 mphomas\nEstimated primary completion: February 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07222631
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091424-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310210
DTEND;VALUE=DATE:20310211
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT05091424)
DESCRIPTION:Rituxan (Rituximab)\, phase 1\, Chronic Lymphocytic Leukemia.\n
 Study: A Study Evaluating the Safety\, Efficacy\, and Pharmacokinetics of 
 Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Pa
 rticipants With Relapsed or Refractory Chronic Lymphocytic Leukemia\nEstim
 ated primary completion: 10 February 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05091424
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03418038-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310222
DTEND;VALUE=DATE:20310223
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03418038)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Re
 fractory Lymphoma\, CCUS\, and Chronic Myelomonocytic Leukemia\nEstimated 
 primary completion: 22 February 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03418038
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299331-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Rituxan (Rituximab): Phase na readout est. (NCT07299331)
DESCRIPTION:Rituxan (Rituximab)\, phase na.\nStudy: Zanubrutinib\, Rituxima
 b\, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
 \nEstimated primary completion: 30 April 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07299331
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05991388-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT05991388)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3.\nStudy: A Global Study of Nove
 l Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-H
 odgkin Lymphoma\nEstimated primary completion: 1 May 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05991388
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662928-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07662928)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Epcoritamab in Combinati
 on With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL)\, The BE
 DROCK Study\nEstimated primary completion: 30 May 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07662928
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06363994-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310625
DTEND;VALUE=DATE:20310626
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06363994)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: A Global Phase 3 Study o
 f Orelabrutinib+BR Vs.BR in Pts with TN MCL\nEstimated primary completion:
  25 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06363994
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341205-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06341205)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Personalized Rituximab T
 reatment Based on Artificial Intelligence in Membranous Nephropathy (iRITU
 X)\nEstimated primary completion: 31 August 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06341205
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900401-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05900401)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Delayed Tolerance Thro
 ugh Mixed Chimerism\nEstimated primary completion: December 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05900401
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390956-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06390956)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Pirtobrutinib in Combina
 tion With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONE
 ER-MZL)\nEstimated primary completion: December 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06390956
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509840-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07509840)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Immunomodulatory Therapy
  to Restore Ovarian Function and Improve Fertility in Women With Autoimmun
 e Premature Ovarian Insufficiency\nEstimated primary completion: 31 Decemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075098
 40
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824701-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06824701)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: Tazemetostat in Combinat
 ion With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Ref
 ractory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: January
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06824701
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294677-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07294677)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: CApivasertib\, Venetoc
 lax And Low-intensity chemotheRapY for Adults With ALL/LBL\nEstimated prim
 ary completion: March 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07294677
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06337318-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06337318)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: Co
 mparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tu
 mor Burden Follicular Lymphoma\nEstimated primary completion: 31 March 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06337318
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05898308-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:Rituxan (Rituximab): Phase 4 readout est. (NCT05898308)
DESCRIPTION:Rituxan (Rituximab)\, phase 4.\nStudy: Comparison of a Personal
 ized Maintenance Therapy With the Standard Treatment in Pemphigus\nEstimat
 ed primary completion: 1 May 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05898308
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634471-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20320723
DTEND;VALUE=DATE:20320724
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT07634471)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Follicular Lymphoma.\nStudy: 
 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lympho
 ma (MK-1045-007)\nEstimated primary completion: 23 July 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07634471
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508009-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05508009)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Early Trial of Allogen
 eic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive 
 a Kidney Transplant From the Same Donor\nEstimated primary completion: Oct
 ober 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0550
 8009
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05283720)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study to Evaluate Adve
 rse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab
  in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult 
 Participants With Non-Hodgkin Lymphoma\nEstimated primary completion: Nove
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0528
 3720
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285590-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07285590)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Clinical Trial to Evalua
 te the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients Wit
 h Mantle Cell Lymphoma\nEstimated primary completion: December 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07285590
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06688331-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06688331)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Treatment of Presymptoma
 tic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparatio
 ns and Anti-CD20 Antibody\nEstimated primary completion: December 2032. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06688331
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846489-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20330210
DTEND;VALUE=DATE:20330211
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06846489)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: Acalabrutinib Plus Ritux
 imab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Unt
 reated Mantle Cell Lymphoma\nEstimated primary completion: 10 February 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06846489
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Chronic Lymphocytic Leukemia.
 \nStudy: Study of NX-5948 in Combination With Other Agents in Adults With 
 B-cell Malignancies\nEstimated primary completion: May 2033. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724457-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT07724457)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3.\nStudy: Testing the Addition o
 f a New Anti-Cancer Drug\, Glofitamab to Usual Chemotherapy for Burkitt an
 d Double Hit Lymphoma\nEstimated primary completion: 1 November 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07724457
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412497-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20350501
DTEND;VALUE=DATE:20350502
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06412497)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: MT2023-20: Hematopoietic
  Cell Transplant With Reduced Intensity Conditioning and Post-transplant C
 yclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bon
 e Marrow Failure.\nEstimated primary completion: 1 May 2035. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06412497
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220187-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20351001
DTEND;VALUE=DATE:20351002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07220187)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Adding Pirtobrutinib to the Usual Treatment for People With Newly 
 Diagnosed Richter Transformation\, The PIRAMID Trial\nEstimated primary co
 mpletion: 1 October 2035. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07220187
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986382-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20370731
DTEND;VALUE=DATE:20370801
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT06986382)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: Phase 1b/2a Trial of A
 llogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor Af
 ter TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/o
 r Early-onset Medically Refractory Crohn Disease\nEstimated primary comple
 tion: July 2037. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06986382
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06191744)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: St
 udy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab 
 and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease 
 Activity in Adult Participants With Previously Untreated Follicular Lympho
 ma\nEstimated primary completion: November 2037. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976763-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20380831
DTEND;VALUE=DATE:20380901
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05976763)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: Testing Continuous Versu
 s Intermittent Treatment With the Study Drug Zanubrutinib for Older Patien
 ts With Previously Untreated Mantle Cell Lymphoma\nEstimated primary compl
 etion: 31 August 2038. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05976763
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973096-4915@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20420731
DTEND;VALUE=DATE:20420801
SUMMARY:Rituxan (Rituximab): Phase 1 readout est. (NCT06973096)
DESCRIPTION:Rituxan (Rituximab)\, phase 1.\nStudy: CART-EGFR-IL13Ra2 in New
 ly Diagnosed GBM Following Initial Radiotherapy\nEstimated primary complet
 ion: July 2042. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritux
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06973096
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
